Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
F HOFFMANN-LA ROCHE AG	BASEL SUI

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....

• 2014 Application Filing Year
• A61K Class
• 14144 Applications Filed
• 11600 Patents Issued To-Date
• 82.02 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Chatterji, Ashish	East Brunswick, US	27	42
# of filed Patents : 27 Total Citations : 42
Huang, Jingjun	Monmouth Junction, US	17	23
# of filed Patents : 17 Total Citations : 23
Koennings, Stephanie	Bottmingen, CH	8	4
# of filed Patents : 8 Total Citations : 4
Lindenstruth, Kai	Loerrach, DE	11	6
# of filed Patents : 11 Total Citations : 6
Sandhu, Harpreet	West Orange, US	11	6
# of filed Patents : 11 Total Citations : 6
Shah, Navnit	Clifton, US	12	129
# of filed Patents : 12 Total Citations : 129

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• 10 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Nov 21, 2026

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2015/0140,087

Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists

---

Abstract

---

Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.